ASCO 2026 | Impact of mRNA SARS-CoV-2 vaccination on CAR T-cell therapy outcomes in hematologic malignancies
Jowan Al-Nusair, MD, Marshall University, Huntington, WV, discusses the impact of mRNA SARS-CoV-2 vaccination on CAR T-cell therapy outcomes in patients with hematologic malignancies, presenting findings from a multi-center real-world analysis that showed improved overall survival (OS) and lower risks of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in vaccinated patients. Dr Al-Nusair highlights the importance of these results, which suggest that mRNA SARS-CoV-2 vaccination may be beneficial for patients receiving CAR T-cell therapy, and notes that prospective studies are needed to further validate these findings and explore the optimal timing of vaccination. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
